Research location
Donostia / San Sebastian
Gipuzkoa, Spain
Advertisement
Research activity in Donostia / San Sebastian
Gipuzkoa, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 28 trials and 28 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Donostia / San Sebastian
28 linked trials · page 1 of 1Heart Failure in Women: Epidemiological and Prognostic InsightsNCT07847983 · 2026-09-17 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation
RECRUITING
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast CancerNCT04889924 · 2021-06-11 · 1 site observation
RECRUITING
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)NCT06698042 · 2024-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486 · 2023-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerNCT05654623 · 2023-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PDNCT05357989 · 2022-08-03 · 1 site observation
COMPLETED
Sukalmena InAge: Nutritional-culinary Programme to Promote Adherence to a Healthy Dietary Pattern.NCT04908163 · 2021-05-26 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)NCT04152863 · 2020-06-05 · 1 site observation
TERMINATED
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)NCT03867084 · 2019-05-28 · 1 site observation
COMPLETED
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor FluctuationsNCT03877510 · 2019-04-03 · 1 site observation
COMPLETED
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseNCT03887455 · 2019-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSNCT03650114 · 2018-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsNCT03631199 · 2018-12-21 · 1 site observation
TERMINATED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · 2018-12-18 · 1 site observation
COMPLETED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsNCT03670953 · 2018-11-06 · 1 site observation
COMPLETED
Effect of a Group Intervention Program Based on Acceptance and Mindfulness on the Physical and Emotional Well-being of Overweight and Obese IndividualsNCT03718728 · 2018-11-03 · 1 site observation
COMPLETED
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)NCT03553836 · 2018-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Predictive Models of Readmission in Heart FailureNCT03300791 · 2017-09-28 · 1 site observation
COMPLETED
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentNCT02962414 · 2017-08-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)NCT03179436 · 2017-07-02 · 1 site observation
COMPLETED
Nivolumab in the Real World: Analysis of the Expanded Use in Spanish PatientNCT03132493 · 2017-06-01 · 1 site observation
COMPLETED
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseNCT02956486 · 2016-10-20 · 1 site observation
TERMINATED
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot UlcersNCT02447172 · 2015-06-01 · 1 site observation
COMPLETED
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerNCT02446444 · 2014-03-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer PatientsNCT00432172 · 2007-04-24 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.